TCMD:NASDAQTactile Systems Technology, Inc. Analysis
Data as of 2026-05-26 - not real-time
$25.06
Latest Price
7/10Risk
Risk Level: Medium
Executive Summary
Tactile Systems Technology (TCMD) is trading around $25.06, well below its DCF‑derived fair value of $51.33, implying an upside of roughly 57% if the model holds. The company posted a robust 22.8% revenue growth YoY, driven by strong demand for its pneumatic compression devices, and maintains an impressive 76% gross margin despite a modest negative operating margin. Forward earnings estimates suggest a forward PE of 16.65, markedly lower than the trailing PE of 28.8 and the industry average PE of 27.4, reinforcing the undervalued narrative. Analyst sentiment is overwhelmingly positive, with a Zacks Rank 1 Strong Buy and a median price target of $40, reflecting a potential 60%+ price appreciation.
Technical indicators are supportive: the stock sits above its 20‑day (24.01) and 50‑day (24.92) SMAs, the MACD histogram is positive indicating bullish momentum, and the RSI at 53 signals a neutral but not overbought condition. Volatility remains high at nearly 49% (30‑day) and beta is modest at 0.73, suggesting price swings but limited market‑wide correlation. Recent upgrades from B. Riley and Zacks, coupled with decreasing volume trends, point to a cautious yet optimistic short‑term outlook.
Technical indicators are supportive: the stock sits above its 20‑day (24.01) and 50‑day (24.92) SMAs, the MACD histogram is positive indicating bullish momentum, and the RSI at 53 signals a neutral but not overbought condition. Volatility remains high at nearly 49% (30‑day) and beta is modest at 0.73, suggesting price swings but limited market‑wide correlation. Recent upgrades from B. Riley and Zacks, coupled with decreasing volume trends, point to a cautious yet optimistic short‑term outlook.
Market Outlook
Short Term
< 1 yearPositive
Model confidence: 7/10
Key Factors
- Price above short‑term SMAs indicating bullish bias
- Analyst upgrades and strong buy recommendation
- Support level at $20.53 provides downside cushion
Medium Term
1–3 yearsPositive
Model confidence: 8/10
Key Factors
- Undervalued DCF fair value with ~57% upside
- Robust revenue growth and high gross margins
- Forward PE compression to 16.6 suggests earnings acceleration
Long Term
> 3 yearsPositive
Model confidence: 8/10
Key Factors
- Sustained market demand for chronic‑disease medical devices
- Strong cash position relative to modest debt
- Long‑term upside potential reflected in analyst price targets
Key Metrics & Analysis
Financial Health
Revenue Growth22.80%
Profit Margin5.91%
P/E Ratio28.8
ROE9.59%
ROA7.31%
Debt/Equity6.96
P/B Ratio2.6
Op. Cash Flow$42.1M
Free Cash Flow$33.5M
Industry P/E27.4
Technical Analysis
TrendNeutral
RSI53.6
Support$20.53
Resistance$27.57
MA 20$24.01
MA 50$24.92
MA 200$22.90
MACDBullish
VolumeDecreasing
Fear & Greed Index91.05
Valuation
Fair Value$51.33
Target Price$39.50
Upside/Downside57.62%
GradeUndervalued
TypeGrowth
Risk Assessment
Beta0.73
Volatility48.87%
Sector RiskMedium
Reg. RiskMedium
Geo RiskLow
Currency RiskLow
Liquidity RiskMedium
Similar Tickers
This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.